ArticleRMD open2024

Correction: Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from japan and south korea.

PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.